Evidence map›Paper›PMID 39913046›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

New evidence for miRNA testing in head and neck squamous cell cancer patients.

Blanca Pilar Galindo Torres, Raquel Alcaraz Ortega, Patricia Saiz López, María Isabel Adiego Leza, María Del Mar Moradillo Renuncio, Carlos García Girón, Miguel Víctor Grijalba Uche

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Potential of hTERT mRNA for the management of advanced head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Blanca Pilar Galindo TorresServicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain. bgalindot@saludcastillayleon.es.ORCID http://orcid.org/0000-0002-0842-4356
Raquel Alcaraz OrtegaUnidad de Investigación, Hospital Universitario de Burgos, Burgos, España.ORCID http://orcid.org/0000-0002-7501-5798
Patricia Saiz LópezServicio Anatomía Patológica, Hospital Universitario de Burgos, Burgos, Spain.ORCID http://orcid.org/0000-0001-7106-5192
María Isabel Adiego LezaServicio Otorrinolaringología, Hospital Universitario Miguel Servet, Zaragoza, Spain.ORCID http://orcid.org/0000-0002-3265-504X
María Del Mar Moradillo RenuncioServicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain.ORCID http://orcid.org/0009-0009-7056-4462
Carlos García GirónServicio Oncología Médica, Hospital Universitario de Burgos, Burgos, Spain.ORCID http://orcid.org/0000-0002-9384-9649
Miguel Víctor Grijalba UcheServicio Otorrinolaringología, Hospital Universitario de Burgos, Burgos, Spain.ORCID http://orcid.org/0000-0002-3956-6007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer. METHODS/PATIENTS: An observational, longitudinal, prospective, analytical study was conducted, with a case-control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.

resultsSeventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R

conclusionOur findings suggest that the evaluation of certain miRNAs' expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.

Indexed as

Biomarkers, TumorHead and Neck NeoplasmsMicroRNAsSquamous Cell Carcinoma of Head and NeckAdultAgedCase-Control StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisProspective StudiesBiomarkers, TumorMicroRNAsDiagnosisHead and neck squamous cell cancerLiquid biopsyMicroRNAMonitoringPlasma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.